AlphAIalphai — Financial news for AI agents
MarketBeatDEC 213 min read$MIST

Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen

Milestone Pharmaceuticals (NASDAQ:MIST) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, contributing to a consensus "Moderate Buy" rating among analysts with an average target price of $8.00. The stock is currently trading around $2.15, and institutional ownership is notably high at 86.18%, indicating significant hedge fund interest. The company recently surpassed quarterly EPS estimates, though negative EPS is still projected for the full fiscal year.

Original reporting
MarketBeat · MarketBeat
Published Dec 21, 2025, 6:25 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 21, 2025, 7:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen — source image
Source · MarketBeat
Decision brief

The 30-second read

$MISTBullishMed
01

Why it matters

The upgrade may reflect improved investor sentiment, but fundamental concerns remain.

02

Market read

The news is moderately relevant for traders interested in biotech stocks, especially those with high institutional ownership.

03

What to watch

Potential regulatory hurdles or clinical trial setbacks could adversely affect stock performance.

Timing: short-term (next 1-3 months)

Background

Milestone Pharmaceuticals recently surpassed quarterly EPS estimates, indicating operational strength, but faces full-year earnings challenges.

Company-level read

Ticker impact

$MISTBullishMedium confidence
Context

The news pertains directly to Milestone Pharmaceuticals, impacting its stock outlook.

Expected impact

Moderate upward price movement expected over the next 1-3 months, approximately 10-15%.

Evidence & confidence

The upgrade and institutional interest support a positive bias, but full-year EPS concerns temper enthusiasm.

Market effects

Sector

Potential positive sentiment for biotech and life sciences sectors, especially small-cap companies with similar profiles.

Regional

Limited regional impact; primarily US-focused due to NASDAQ listing.

Global

Minimal global market influence.

Counterpoint

What could challenge this read

The negative full-year EPS projection could signal underlying financial challenges, risking a decline despite recent upgrades.

Key entities

  • Company
    Milestone Pharmaceuticals

    A biotech firm focused on cardiovascular and neurological therapies.

Read at source← All news

Related articles

AUG 12
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

finanznachrichten.de7 min
AUG 12
$MISTMed

Milestone Pharmaceuticals Inc. (MIST): Results of Operations and Financial Condition

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage

SEC EDGAR 8-K6 min
AUG 12
$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

finanznachrichten.de4 min
AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 12
$FGLMed

Founder Group Limited Secures Second Aquaculture Contract, a US$1.4 million 1.78 MW rooftop system for a Kedah shrimp Farm

Founder Group Limited (NASDAQ: FGL) said its subsidiary Founder Energy Sdn Bhd signed a turn-key EPCC contract for a 1.78 MW-peak rooftop solar system for a shrimp farming and processing facility in Ayer Hitam, Kedah. The contract is valued at about RM5.58 million (US$1.37 million). The company also cited Malaysia RE policy targets and plans for 25-year operations.

thestarphoenix.com4 min
AUG 12
$AEHRMed

Aehr Test Systems: Aehr Receives $22 Million Follow-On Order for AI Processor Wafer-Level Burn-In Systems

Aehr Test Systems (NASDAQ:AEHR) said it received a $22 million follow-on production order from its lead wafer-level AI processor customer. The order includes multiple FOX-XP wafer-level burn-in systems plus FOX WaferPak contactors and auto aligners, testing nine 300mm wafers per system. Aehr expects shipment over six months for installation in Taiwan.

finanznachrichten.de4 min